Aβ1-6A2V(D) peptide, effective on Aβ aggregation, inhibits tau misfolding and protects the brain after traumatic brain injury

Bloom GS. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71:505–8.

Article  PubMed  Google Scholar 

Latimer CS, Stair JG, Hincks JC, Currey HN, Bird TD, Keene CD, et al. TDP-43 promotes tau accumulation and selective neurotoxicity in bigenic Caenorhabditis elegans. Dis Models Mechanisms. 2022;15:dmm049323.

Article  CAS  Google Scholar 

Larkin HD, Lecanemab, Gains FDA. Approval for Early Alzheimer Disease. JAMA. 2023;329:363.

Article  PubMed  Google Scholar 

Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep. 2018;8:6412.

Article  PubMed  PubMed Central  Google Scholar 

Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurol. 2022;79:13–21.

Article  PubMed  Google Scholar 

Catania M, Giaccone G, Salmona M, Tagliavini F, Di Fede G. Dreaming of a New World Where Alzheimer’s Is a Treatable Disorder. Front Aging Neurosci. 2019;11:317–24.

Sharma P, Srivastava P, Seth A, Tripathi PN, Banerjee AG, Shrivastava SK. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies. Prog Neurobiol. 2019;174:53–89.

Article  CAS  PubMed  Google Scholar 

Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opin Investig Drugs. 2017;26:735–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cacabelos R. Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years? Expert Opin Drug Discov. 2018;13:523–38.

Article  CAS  PubMed  Google Scholar 

Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6:37.

Article  PubMed  PubMed Central  Google Scholar 

Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6.

Article  CAS  PubMed  Google Scholar 

Imbimbo BP, Ippati S, Watling M, Balducci C. A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. Alzheimer’s Dement. 2022;18:1008–37.

Article  CAS  Google Scholar 

Jadhav S, Avila J, Schöll M, Kovacs GG, Kövari E, Skrabana R, et al. A walk through tau therapeutic strategies. Acta Neuropathologica Commun. 2019;7:22.

Article  Google Scholar 

Di Fede G, Catania M, Morbin M, Rossi G, Suardi S, Mazzoleni G, et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science. 2009;323:1473–7.

Article  PubMed  PubMed Central  Google Scholar 

Cantu’ L, Colombo L, Stoilova T, Demé B, Inouye H, Booth R, et al. The A2V mutation as a new tool for hindering Aβ aggregation: A neutron and x-ray diffraction study. Sci Rep. 2017;7:5510.

Article  PubMed  PubMed Central  Google Scholar 

Catania M, Colombo L, Sorrentino S, Cagnotto A, Lucchetti J, Barbagallo MC, et al. A novel bio-inspired strategy to prevent amyloidogenesis and synaptic damage in Alzheimer’s disease. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01745-x.

Di Fede G, Catania M, Morbin M, Giaccone G, Moro ML, Ghidoni R, et al. Good gene, bad gene: new APP variant may be both. Prog Neurobiol. 2012;99:281–92.

Article  PubMed  Google Scholar 

Diomede L, Romeo M, Cagnotto A, Rossi A, Beeg M, Stravalaci M, et al. The new β amyloid-derived peptide Aβ1-6A2V-TAT(D) prevents Aβ oligomer formation and protects transgenic C. elegans from Aβ toxicity. Neurobiol Dis. 2016;88:75–84.

Article  CAS  PubMed  Google Scholar 

Messa M, Colombo L, del Favero E, Cantù L, Stoilova T, Cagnotto A, et al. The peculiar role of the A2V mutation in amyloid-β (Aβ) 1-42 molecular assembly. J Biol Chem. 2014;289:24143–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diomede L, Di Fede G, Romeo M, Bagnati R, Ghidoni R, Fiordaliso F, et al. Expression of A2V-mutated Aβ in Caenorhabditis elegans results in oligomer formation and toxicity. Neurobiol Dis. 2014;62:521–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cimini S, Sclip A, Mancini S, Colombo L, Messa M, Cagnotto A, et al. The cell-permeable Aβ1-6A2VTAT(D) peptide reverts synaptopathy induced by Aβ1-42wt. Neurobiol Dis. 2016;89:101–11.

Article  CAS  PubMed  Google Scholar 

Di Fede G, Catania M, Maderna E, Morbin M, Moda F, Colombo L, et al. Tackling amyloidogenesis in Alzheimer’s disease with A2V variants of Amyloid-β. Sci Rep. 2016;6:20949.

Article  PubMed  PubMed Central  Google Scholar 

Maloney JA, Bainbridge T, Gustafson A, Zhang S, Kyauk R, Steiner P, et al. Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. J Biol Chem. 2014;289:30990–31000.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benilova I, Gallardo R, Ungureanu A-A, Castillo Cano V, Snellinx A, Ramakers M, et al. The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-β (Aβ) aggregation. J Biol Chem. 2014;289:30977–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Natale C, Barzago MM, Diomede L. Caenorhabditis elegans Models to Investigate the Mechanisms Underlying Tau Toxicity in Tauopathies. Brain Sci. 2020;10:E838.

Article  Google Scholar 

Zanier ER, Barzago MM, Vegliante G, Romeo M, Restelli E, Bertani I, et al. C. elegans detects toxicity of traumatic brain injury generated tau. Neurobiol Dis. 2021;153:105330.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Natale C, Barzago MM, Colnaghi L, De Luigi A, Orsini F, Fioriti L, et al. A Combined Cell-Worm Approach to Search for Compounds Counteracting the Toxicity of Tau Oligomers In Vivo. Int J Mol Sci. 2022;23:11277.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zanier ER, Bertani I, Sammali E, Pischiutta F, Chiaravalloti MA, Vegliante G, et al. Induction of a transmissible tau pathology by traumatic brain injury. Brain. 2018;141:2685–99.

PubMed  PubMed Central  Google Scholar 

Risling M, Smith D, Stein TD, Thelin EP, Zanier ER, Ankarcrona M, et al. Modelling human pathology of traumatic brain injury in animal models. J Intern Med. 2019;285:594–607.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmidt ML, Zhukareva V, Newell KL, Lee VM, Trojanowski JQ. Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer’s disease. Acta Neuropathol. 2001;101:518–24.

Article  CAS  PubMed  Google Scholar 

Agrawal S, Leurgans SE, James BD, Barnes LL, Mehta RI, Dams-O’Connor K, et al. Association of Traumatic Brain Injury With and Without Loss of Consciousness With Neuropathologic Outcomes in Community-Dwelling Older Persons. JAMA Netw Open. 2022;5:e229311.

Article  PubMed  PubMed Central  Google Scholar 

Shively S, Scher AI, Perl DP, Diaz-Arrastia R. Dementia resulting from traumatic brain injury: what is the pathology? Arch Neurol. 2012;69:1245–51.

Article  PubMed  PubMed Central  Google Scholar 

Li Y, Li Y, Li X, Zhang S, Zhao J, Zhu X, et al. Head Injury as a Risk Factor for Dementia and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of 32 Observational Studies. PLoS One. 2017;12:e0169650.

Article  PubMed  PubMed Central  Google Scholar 

Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409–21.

Article  CAS  PubMed  Google Scholar 

Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. J Pharm Pharmacother. 2010;1:94–99.

Article  Google Scholar 

Moro F, Fossi F, Magliocca A, Pascente R, Sammali E, Baldini F, et al. Efficacy of acute administration of inhaled argon on traumatic brain injury in mice. Br J Anaesth. 2021;126:256–64.

Article  CAS  PubMed  Google Scholar 

Moro F, Pischiutta F, Portet A, Needham EJ, Norton EJ, Ferdinand JR, et al. Ageing is associated with maladaptive immune response and worse outcome after traumatic brain injury. Brain Commun. 2022;4:fcac036.

Article  PubMed  PubMed Central  Google Scholar 

Brody DL, Mac Donald C, Kessens CC, Yuede C, Parsadanian M, Spinner M, et al. Electromagnetic Controlled Cortical Impact Device for Precise, Graded Experimental Traumatic Brain Injury. J Neurotrauma. 2007;24:657–73.

Article  PubMed  Google Scholar 

Hanson LR, Fine

留言 (0)

沒有登入
gif